Navigation Links
Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
Date:10/23/2007

http://www.genaera.com" target="_new">http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Gen
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
(Date:8/31/2015)... ... August 31, 2015 , ... ... management device that could effectively deliver oxygen with a lower risk of failure," ... better way, I invented the Adam Device." , The Adam Device offers a ...
(Date:8/31/2015)... Tennessee (PRWEB) , ... August ... ... of Lifestyle Medicine (ACLM), the nation’s medical professional association for physicians and ... in conjunction with the Lifestyle Medicine Foundation, announced today the establishment of ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... MeYou ... recently enhanced its mobile walking app, Walkadoo , by including an in-app step ... goals that adapt to each person’s walking habits. Rather than broadly assign every Walkadoo ...
(Date:8/31/2015)... ... 2015 , ... There’s big news for ZendyHealth , a Los Angeles-based ... Consumer driven health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought on ... company, and another to answer customers’ questions directly. , John Young, CEO of Consumerdriven, ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3
... question results of small Polish study , , TUESDAY, Jan. ... left main coronary artery appeared to give better short-term results ... experts cast some doubt on the clinical value of the ... University of Silesia, compared results of surgery versus stenting in ...
... Educational teleconference on medical therapies to feature Mayo Clinic ... ... 29 Crohn,s disease and ulcerative,colitis patients, caregivers, and healthcare professionals ... Medications?" This,free, live, interactive teleconference through the Crohn,s & Colitis,Foundation will ...
... confused with ... at least one other drug, ROCKVILLE, Md., Jan. 29 ... (USP),revealed that more than 1,400 commonly used drugs are involved in errors,linked ... the MEDMARX report, 1.4% of the errors resulted in patient harm,including seven ...
... Arcadian Health Plan, Inc., a,leading provider of ... its benefits for 2008 and expanded into the,state ... successful rollouts in,Oklahoma, Georgia, South Carolina and Maine., ... premiums, free annual,physicals and flu shots, dental benefits, ...
... Plan, Inc.,a leading provider of Medicare Advantage health plans ... expanded into the,state of Oklahoma. This comes on the ... Maine., Highlights of these plans include $0 premiums ... benefits, and an ever-expanding,provider and hospital network., "We,ve ...
... in Homes and Cars, GENEVA, Jan. 29 It,s ... world,s youth - breathe air polluted,by tobacco smoke. People who ... others to a dangerous mix of toxins including nicotine, carbon,monoxide, ... children to chronic health risks:, -- Increases a ...
Cached Medicine News:Health News:Stents Slightly Better Than Bypass for Blocked Left Coronary Artery 2Health News:Stents Slightly Better Than Bypass for Blocked Left Coronary Artery 3Health News:Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals 2Health News:U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide 2Health News:U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide 3Health News:Bright Options for Medicare Beneficiaries in Louisiana 2Health News:Expanded Options for Medicare Beneficiaries in Oklahoma 2Health News:Global Initiative To Protect Children From Secondhand Smoke 2Health News:Global Initiative To Protect Children From Secondhand Smoke 3
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
... Normal and Abnormal ... Assays of vWF, D-dimer ... on STA© Analyzers. For ... vWF (#0518),STA© LIATEST© D-DI ...
CRP high sensitivity calibrator series...
Inquire...
Medicine Products: